Effect of Prophylactic Versus Preemptive Lamivudine Treatment and Tenofovir on HBsAg (+) Kidney Transplant Recipients
EXPERIMENTAL AND CLINICAL TRANSPLANTATION, cilt.13, sa.1, ss.35-40, 2015 (SCI-Expanded)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 13 Sayı: 1
- Basım Tarihi: 2015
- Doi Numarası: 10.6002/ect.2013.0280
- Dergi Adı: EXPERIMENTAL AND CLINICAL TRANSPLANTATION
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.35-40
- Akdeniz Üniversitesi Adresli: Evet
Özet
Objectives: Chronic hepatitis B virus infection remains a clinical problem for HBsAg (+) kidney transplant recipients. Lamivudine is the approved treatment; however, there are contrary views about optimal initiation. In case of resistance, novel nucleoside analogs should be considered but experience is limited.